Adamas Pharmaceuticals Inc Quick Ratio (ADMS) starting from the third quarter 2021 to third quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Adamas Pharmaceuticals Inc  (NASDAQ: ADMS)

Adamas Pharmaceuticals Inc's Quick Ratio

ADMS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2021, Quick Ratio fell to 3.49 below Adamas Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 399 other companies have achieved higher Quick Ratio than Adamas Pharmaceuticals Inc in third quarter 2021. While Quick Ratio total ranking in the third quarter 2021 has deteriorated compared to the prior quarter from 1145 to 1464.

Explain Quick Ratio?
How much Cash & cash equivalents ADMS´s has?
What are ADMS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADMS Quick Ratio (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1		 (Dec 31 2020)
Q4		 (Sep 30 2020)
Q3
Y / Y Current Liabilities Change -24.27 % 2.87 % 22.7 % 29.39 % 19.46 %
Y / Y Cash & cash equivalent Change -10.14 % -11.65 % 8.28 % -37.13 % -38.45 %
Quick Ratio MRQ 3.49 4.19 4.28 2.39 2.94
ADMS's Total Ranking # 1464 # 1145 # 973 # 508 # 617
Seq. Current Liabilities Change 9.25 % -25.2 % -16.32 % 10.74 % 48.41 %
Seq. Cash & cash equivalent Change -9.05 % -26.81 % 49.74 % -9.85 % -10.58 %



Quick Ratio third quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 400
Healthcare Sector # 697
Overall Market # 1464


Quick Ratio Statistics
High Average Low
24.14 9.52 2.39
(Jun 30 2014)   (Dec 31 2020)




Financial Statements
Adamas Pharmaceuticals Inc's Current Liabilities $ 24 Millions Visit ADMS's Balance sheet
Adamas Pharmaceuticals Inc's Cash & cash equivalent $ 83 Millions Visit ADMS's Balance sheet
Source of ADMS's Sales Visit ADMS's Sales by Geography


Cumulative Adamas Pharmaceuticals Inc's Quick Ratio

ADMS's Quick Ratio for the trailling 12 Months

ADMS Quick Ratio

 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months		 (Sep 30 2020)
12 Months
Y / Y Current Liabilities TTM Growth 6.07 % 19.38 % 13.56 % 2.29 % -1.04 %
Y / Y Cash & cash equivalent TTM Growth -13.77 % -21.83 % -28.7 % -38.56 % -38.4 %
Quick Ratio TTM 3.49 3.34 3.46 3.54 4.29
Total Ranking TTM # 4538 # 524 # 481 # 723 # 539
Seq. Current Liabilities TTM Growth -6.51 % 0.52 % 4.85 % 7.66 % 5.22 %
Seq. Cash & cash equivalent TTM Growth -2.39 % -2.98 % 2.42 % -11.1 % -11.52 %

Quick ratio ranking by company, industry and sector >> Back to ADMS Financial Strength Comparisons >> Go to Compare ADMS Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Adamas Pharmaceuticals Inc's average Cash & cash equivalent, this led to increase in in Adamas Pharmaceuticals Inc's Quick Ratio to 3.49, Quick Ratio remained below ADMS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 496 other companies have achieved higher Quick Ratio than Adamas Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2021 from 524 to 4538.

Explain Quick Ratio?
How much Cash & cash equivalents ADMS´s has?
What are ADMS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 497
Healthcare Sector # 979
Within the Market # 4538


trailing twelve months Quick Ratio Statistics
High Average Low
11.69 8.22 3.34
(Dec 31 2016)   (Jun 30 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2021, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2021 MRQ Cash & cash equivalentSep 30 2021 MRQ Current Liabilities
Intra cellular Therapies Inc   9.57 $ 477.284  Millions$ 49.896  Millions
Atreca inc   9.46 $ 152.886  Millions$ 16.155  Millions
Mirati Therapeutics Inc   9.46 $ 1,154.418  Millions$ 122.079  Millions
Zentalis Pharmaceuticals Inc   9.31 $ 366.791  Millions$ 39.415  Millions
Landos Biopharma Inc   9.25 $ 102.670  Millions$ 11.095  Millions
Cryoport inc   9.25 $ 350.437  Millions$ 37.884  Millions
Alzamend Neuro Inc   9.20 $ 13.573  Millions$ 1.475  Millions
Marinus Pharmaceuticals Inc   9.16 $ 145.101  Millions$ 15.848  Millions
Akero Therapeutics Inc   9.14 $ 215.081  Millions$ 23.540  Millions
Gt Biopharma Inc   9.11 $ 35.713  Millions$ 3.922  Millions
Liquidia Corporation  9.07 $ 64.054  Millions$ 7.064  Millions
F star Therapeutics Inc   9.04 $ 71.050  Millions$ 7.859  Millions
Hoth Therapeutics Inc   9.01 $ 14.477  Millions$ 1.607  Millions
Biovie Inc   9.01 $ 11.351  Millions$ 1.260  Millions
Bolt Biotherapeutics Inc   8.98 $ 212.893  Millions$ 23.695  Millions
Ligand Pharmaceuticals Incorporated  8.90 $ 323.211  Millions$ 36.297  Millions
Concert Pharmaceuticals Inc   8.84 $ 106.223  Millions$ 12.021  Millions
Bicycle Therapeutics Plc  8.60 $ 259.524  Millions$ 30.177  Millions
Opus Genetics Inc   8.58 $ 22.633  Millions$ 2.638  Millions
Y mabs Therapeutics inc   8.51 $ 215.730  Millions$ 25.359  Millions
Catalyst Pharmaceuticals Inc   8.48 $ 174.792  Millions$ 20.614  Millions
Arvinas Inc   8.46 $ 1,544.477  Millions$ 182.508  Millions
United Therapeutics Corporation  8.46 $ 2,000.400  Millions$ 236.500  Millions
Durect Corp  8.45 $ 80.796  Millions$ 9.565  Millions
Ngm Biopharmaceuticals Inc   8.44 $ 383.429  Millions$ 45.440  Millions
Schrodinger Inc   8.42 $ 597.186  Millions$ 70.938  Millions
Agios Pharmaceuticals Inc   8.41 $ 400.224  Millions$ 47.601  Millions
Inmed Pharmaceuticals Inc  8.34 $ 15.389  Millions$ 1.845  Millions
Evoke Pharma Inc   8.31 $ 11.142  Millions$ 1.341  Millions
Io Biotech Inc   8.25 $ 45.477  Millions$ 5.510  Millions

Date modified: 2026-09-08T15:10:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.